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Towards identification of immune and genetic
correlates of severe influenza disease in Indigenous
Australians
E Bridie Clemens1, Emma J Grant1, Zhongfang Wang1, Stephanie Gras2,3, Peta Tipping4, Jamie Rossjohn2,3,5,
Adrian Miller6, Steven YC Tong4,7 and Katherine Kedzierska1,7
Indigenous populations, including Indigenous Australians, are highly susceptible to severe influenza disease and the underlying
mechanisms are unknown. We studied immune and genetic factors that could predicate severe influenza disease in Indigenous
Australians enrolled in the LIFT study: looking into influenza T-cell immunity. To examine CD8+ T-cell immunity, we
characterised human leukocyte antigen (HLA) profiles. HLA typing confirmed previous studies showing predominant usage of
HLA-A*02:01, 11:01, 24:02, 34:01 and HLA-B*13:01, 15:21, 40:01/02, 56:01/02 in Indigenous Australians. We identified
two new HLA alleles (HLA-A*02:new and HLA-B*56:new). Modelling suggests that variations within HLA-A*02:new (but not
HLA-B56:new) could affect peptide binding. There is a relative lack of known influenza epitopes for the majority of these HLAs,
with the exception of a universal HLA-A*02:01-M158 epitope and proposed epitopes presented by HLA-A*11:01/HLA-A*24:02.
To dissect universal CD8+ T-cell responses, we analysed the magnitude, function and T-cell receptor (TCR) clonality of
HLA-A*02:01-M158
+CD8+ T cells. We found comparable IFN-γ, TNF and CD107a and TCRαβ characteristics in Indigenous
and non-Indigenous Australians, suggesting that the ~15% of Indigenous people that express HLA-A*02:01 have universal
influenza-specific CD8+ T-cell immunity. Furthermore, the frequency of an influenza host risk factor, IFITM3-C/C, was
comparable between Indigenous Australians and Europeans, suggesting that expression of this allele does not explain increased
disease severity at a population level. Our study indicates a need to identify novel influenza-specific CD8+ T-cell epitopes
restricted by HLA-A and HLA-B alleles prevalent in Indigenous populations for the rational design of universal T-cell vaccines.
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Indigenous populations are at substantially higher risk of hospitalisa-
tion and morbidity from influenza infection. Up to 10–20% of
Indigenous Australians died from pandemic influenza in 1919
compared with o1% of non-Indigenous Australians.1 Similarly,
although Indigenous Australians comprise 2.5% of the Australian
population, they accounted for 16% of patients hospitalised with
pandemic (p) H1N1 and 9.7% of those admitted to ICU.2 Studies
from the Northern Territory, Queensland and Western Australia have
found that Indigenous Australians are 3–12 times more likely to be
hospitalised than non-Indigenous Australians. Similar patterns have
been observed in Indigenous populations from New Zealand, Canada
and the United States.3–5 Such greater risk of hospitalisation could
reflect higher infection rates due to crowded living conditions, and
also increased rates of chronic disease and comorbidities that lead to
more severe outcome. In this setting, pre-emptive vaccination is
clearly of significant benefit. However, prior administration of the
currently available vaccines confers no protection against newly
emerged unpredicted influenza viruses. Ultimately, the capacity to
clear influenza virus and recover depends on the immune status of the
individual.
Immune factors and host genetics can lead to increased severity of
influenza disease in some ethnicities. This is exemplified by the
expression of an interferon-induced transmembrane protein 3
(IFITM3) single-nucleotide polymorphism (SNP) rs12252, with the
IFITM3 rs12252-C/C genotype (versus C/T or T/T) being predictive
of early hypercytokinemia and severe influenza-induced disease.
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The IFITM3 C/C genotype is highly prevalent in the Asian population
and correlates with severe pH1N1 and H7N9 disease.6,7 The pre-
valence of the IFITM3-C/C genotype in Indigenous Australians has
not yet been documented.
Differences in influenza-specific T-cell immunity, especially the
protective CD8+ T-cell responses,8–10 can be affected by distinct
human leukocyte antigen (HLA) profiles (HLA restriction) found
across different ethnicities.11 Our recent work showed that Indigenous
populations, including Indigenous Australians and Alaskans, are at
greater risk from severe influenza disease caused by newly emerged
influenza viruses due to a lack of CD8+ T cells directed at universal
influenza epitopes.11 Thus, prolonged and more severe influenza
infection in the Indigenous population might reflect differences in
CD8+ T-cell immunity associated with specific HLA profiles expressed.
Indeed, the computational data suggest a strong correlation between
pH1N1 influenza-induced mortality and the expression of HLA-A24,12
an allele highly prevalent in Indigenous Australians and Alaskans.13
Previous studies also suggest that some HLA molecules of Indigenous
Australians differ from those that predominate in non-Indigenous
Australians.14–16 Thus, HLAs expressed in Indigenous populations
may bind different viral peptides and induce distinct CD8+ T-cell
responses in comparison with non-Indigenous individuals. To date,
there are no data on influenza-specific CD8+ T-cell responses, in the
context of HLA restriction, in Indigenous Australians. Given the recent
emergence of new influenza viruses capable of infecting humans
(H7N9, H6N5 and H10N8), there is an urgent need to understand the
immune correlates, and especially the effectiveness of CD8+ T-cell
immunity within the vulnerable Indigenous communities.
Here we studied influenza-specific CD8+ T-cells epitopes in a
cohort of Indigenous Australians enrolled in the LIFT study: looking
into influenza T-cell immunity. Our HLA analysis verified previous
reports of predominant usage of HLA-A*02:01, 11:01, 24:02, 34:01
and HLA-B*13:01, 15:21, 40:01/02, 56:01/02 in Indigenous
Australians, and identified new HLA-A*02 and HLA-B*56 alleles.
We showed a relative lack of known epitopes for these highly
represented HLAs and analysed the magnitude, quality and clonality of
CD8+ T cells directed at a universal HLA-A*02:01-M158 epitope. We
found comparable characteristics of HLA-A*02:01-M158
+CD8+ T cells
in Indigenous and non-Indigenous Australians. Further, we deter-
mined low population frequency of IFITM3-C/C alleles in Indigenous
Australians. We propose that identification of novel immunodominant
influenza-specific CD8+ T cell epitopes restricted by HLA alleles
prevalent in the Indigenous populations should be a priority for the
rational design of new influenza vaccine strategies.
RESULTS
‘Looking into inFluenza T cell immunity’ (LIFT) cohort
We recruited 82 Australian Indigenous donors (LIFT01-LIFT083;
Supplementary Table S1) in Darwin, Northern Territory, Australia.
Participants included Indigenous patients at the Royal Darwin
Hospital admitted with non-influenza related diagnoses and healthy
volunteers in the Darwin region. The study was explained to potential
Figure 1 HLA class I allele expression in Indigenous Australians from the Top End. DNA typing of HLA-A, -B and -C alleles was performed for 82 Indigenous
Australian individuals from the Top End of the Northern Territory in Australia (LIFT cohort; 2n=164). The range and frequency of HLA class I allele
expression are shown compared against previous studies of HLA class I expression in Indigenous Australians obtained from NCBI dbMHC Anthropology
Resources (available online at www.ncbi.nlm.nih.gov/gv/mhc/ihwg.cgi?cmd=page&page=AnthroMain) (HLA-A, 2n=810; HLA-B, 2n=812; HLA-C,
2n=764). The sample size was 2n as each individual donor contributed two separate alleles to the analysis.
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participants by Indigenous research staff with the use of culturally
appropriate flipcharts and all participants provided written informed
consent. The study was approved by the Human Research Ethics
Committee (HREC) of the Northern Territory Department of Health
and Menzies School of Health Research, and included review by the
Aboriginal Ethics Sub-committee of the HREC. The median age of
participants was 45 years (interquartile range 30, 55) and 42 (52%)
were male.
Restricted HLA allele expression in Indigenous Australians from the
Top End
Our analysis of 82 LIFT donors showed that HLA allele expression in
Top End Indigenous Australians is relatively restricted for both HLA
class I (Figure 1) and HLA class II (Figure 2). LIFT donors expressed a
more restricted range of HLA alleles compared with Australian
Caucasians . The four main HLA-A alleles in LIFT Indigenous donors
(HLA-A*02:01, 11:01, 24:02 and 34:01) accounted for 79% of HLA-A
alleles, whereas the four main HLA-B alleles (HLA-B*13:01, 15:21,
40:01/02, 56:01/02) accounted for 47% of HLA-B alleles (Figure 1).
The main HLA-C alleles were HLA-C*01:02, 04:01/02, 07:02
and 15:02.
Similarly, expression of HLA class II alleles was largely limited
(Figure 2). The most dominant HLAs were HLA-DRB1*06:03,
HLA-DPB*102:01, 04:01, 05:01 and HLA-DQB1*03:01, 04:02, 05:03
and 06:01. Our data are in accordance with previous reports.17
Overall, HLA distribution in our LIFT cohort was similar to those
found in previous Indigenous cohorts from Cape York, Groote
Eylandt, Kimberley and Yuendumu regions (NCBI dbMHC Anthro-
pology Resources; Supplementary Table S2). Thus, there appears to be
a HLA conservation between geographically distinct Indigenous
groups that were unlikely to have had extensive interaction.
New HLA-A*02 and HLA-B*56 alleles in Indigenous Australians
Molecular sequencing of donors LIFT026 and LIFT053 identified two
new HLA alleles thus far unique to Indigenous Australians. In
LIFT053, the new HLA-A*02 allele differed from HLA-A*02:35:01 at
four nucleotide positions affecting three codons. The first nucleotide
substitution occurs at codon 62 (GGG to CGG) and results in an
amino-acid (aa) change of glycine to arginine. The second and third
nucleotide substitutions at codon 63 (GAG to AAC) result in an aa
change from glutamic acid to asparagine. A change in a nucleotide at
codon 90 (GCC to GAC) results in an aa change from alanine to
aspartic acid. Sequencing was verified on two occasions by the analysis
of two independent samples. Position 90 is located in one of the loops
outside the antigen-binding cleft of the HLA molecule, and therefore is
unlikely to change the bound peptide repertoire of the new HLA-A*02
allele. On the other hand, positions 62 and 63 are located within the
antigen binding cleft (Figure 3a), with position 62 exposed to the
solvent and readily available for TCR contact, whereas position 63 is
buried within the cleft and likely interacts with the residue at position
1 of the peptide. The larger arginine 62 of the new HLA-A*02
allele (Figure 3b) will most likely affect TCR interaction. In the
HLA-A*02:35:01 molecule, Glu 63 makes a hydrogen bond with the
main chain of the first residue of the peptide, stabilizing the bound
Figure 2 HLA class II allele expression in Indigenous Australians from the Top End. DNA typing of HLA-DRB1, -DPB1 and -DQB1 was performed for
Indigenous Australian individuals (LIFT cohort; 2n=164). Allele expression is shown as described in Figure 1. Data from NCBI dbMHC Anthropology
Resources represent: HLA-DRB1, 2n=280; HLA-DPB1, 2n=268; HLA-DQB1, 2n=280.
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peptide. In the new HLA-A*02 allele, the Glu 63 is replaced by an Asn
63, which might not be as suited to strongly bind position 1 of the
peptide owing to a smaller side chain (Figure 3c). The change at
position 63 might potentially impact on peptide binding and change
the peptide repertoire of the HLA-A*02:new compared with that of
the HLA-A*02:35:01 molecule. Further studies will determine the
peptide repertoire presented by this new HLA-A02 allele and test their
immunogenicity.
HLA-B*56:new was identified in donor LIFT026. This new allele
differs from B*56:01:01G or B*56:02 at codon 75 (CGA to GGA) and
results in an aa change from arginine to glycine. The Arg75 of
HLA-B*56:01 is located on the α1-helix of the cleft (Figure 3d),
outside the cleft and therefore the change to glycine (Figure 3e) should
not impact T-cell recognition. The HLA residue 75 does not contact
the bound peptide, and the substitution from arginine to glycine
(Figure 3f) is unlikely to impact the peptide repertoire. Therefore, the
HLA-B*56:new and HLA-B*56:01 alleles are likely to bind the same
peptide repertoire.
Dissection of influenza epitopes restricted by HLA-A and HLA-B
alleles prevalent in Indigenous Australians
To understand the breadth of potential CD8+ T-cell epitopes restricted
by HLAs expressed in Indigenous Australians, we analysed epitopes
corresponding to the immunogenic influenza proteins: nucleoprotein
(NP), matrix 1 (M1) and polymerase basic 1 (PB1),18 as outlined in
the Immune Epitope Database (www.immuneepitope.org). We found
that influenza-specific CD8+ T-cell epitopes were previously proposed
for four HLAs common to non-indigenous populations and identified
within our LIFT cohort, including HLA-A*02:01 (40 epitopes), HLA-
A*11:01 (20 epitopes), HLA-A*24:02 (10 epitopes) and HLA-B*40:02
(5 epitopes; Table 1). In contrast, no influenza-specific epitopes have
been identified for the remaining HLAs (HLA-A*02:new, HLA-
A*15:25, HLA-A*34:01, HLA-B*13:01, HLA-B*15:21, HLA-B*40:02,
HLA-B*56:01, HLA-B*56:02, HLA-B*56:new) prominent in our LIFT
cohort or described as distinct to Indigenous Australians (Table 1).
Thus, no influenza-specific CD8+ T-cell epitopes have been yet
proposed for 71% of class I HLA alleles identified in Indigenous
Australians. This suggests a need to identify prominent influenza
epitopes restricted by HLAs associated with Indigenous populations in
order to accurately determine the extent of CD8+ T-cell immunity in
this population. Furthermore, our findings suggest that the immuno-
dominant epitopes in Indigenous Australians are likely to differ from
dominant CD8+ T-cell specificities in Caucasian populations.
Universal CD8+ T-cell immunity directed at the universal
HLA-A*02:01-restricted M158–66 epitope
To the best of our knowledge, there are currently no data published on
influenza-specific CD8+ T-cell responses in the Indigenous Australian
population. It is, however, well documented that HLA-A*02:01-
positive individuals generate prominent CD8+ T-cell responses
towards the viral M158–66 peptide, highly conserved amongst distinct
influenza strains and subtypes.11,19 To understand how robust and
functional M158
+CD8+ T cells are in the ~ 15% of Indigenous donors
who express HLA-A*02:01, we analysed peripheral blood mono-
nuclear cells (PBMCs) from HLA-A*02:01-positive LIFT donors
stimulated with the M158 peptide, a method used routinely to amplify
influenza-specific memory CD8+ T cells.20,21 M158
+CD8+ T-cell
numbers and their functional capacities were assessed on d10 after
the in vitro stimulation. Analysis of 7 LIFT individuals of various ages
revealed the presence of prominent M158
+CD8+ T-cell responses in 6
HLA-A*02:01 donors (LIFT07, LIFT09, LIFT011, LIFT022, LIFT027,
and LIFT029), but not LIFT03, who expressed HLA-A*02:05 (rather
than HLA-A*02:01) positive (Figure 4a). Staining with the A2-M158
tetramer showed robust expansion of influenza-specific CD8+ T cells
on d10 after in vitro stimulation (mean of 4.2% of CD8+ T cells; range
1.23–9.48%).
We next determined the qualitative characteristics of M158
+CD8+
T cells in the LIFT cohort. As high-quality CD8+ T cells simulta-
neously produce multiple cytokines and display killing capacity, we
assessed the production of interferon (IFN)-γ and tumour necrosis
factor (TNF) together with CD107a degranulation following
short-term stimulation (5 h) with the M158 peptide and detection by
Figure 3 Modelling of new HLA class I alleles identified in Top End Indigenous Australians. The top panels show (a) the HLA-A*02:01 cleft, (b) HLA-A*02:
new and (c) a superposition of both HLAs. The HLA cleft is represented in cartoon and the key residues as stick, coloured in white for HLA-A*02:01 and
pink for HLA-A*02:new. The dashed lines represent the interaction between the HLA residue 63 and the peptide residue 1. The bottom panels represent the
(d) HLA-B*56:01 in grey, (e) HLA-B*56:new in cyan and (f) a superposition of both HLAs. The sphere represents the Cα atom of the glycine 75.
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an intracellular cytokine secretion (ICS) assay. Our data showed that
M158
+CD8+ T cells in the LIFT cohort were polyfunctional and
56.68%± 16.3% produced both INF-γ and TNF (Figure 4b). A high
proportion of those cells (66.8%± 18.3%, representing 40.1± 15.7%
of all M158
+CD8+ T cells) also expressed CD107a (Figure 4c).
Clonal characteristics of the universal CD8+ T cells directed at
HLA-A*0201-restricted M158–66 epitope
TCR usage has an important role in determining the quality of the
CD8+ T-cell response to viruses and the outcome of infection.22–25
Previous analyses of M158
+CD8+ T cells, using mainly T-cell
clones, have described the M158-specific TCR repertoire as highly
conserved26,27 and identified clones shared across different
HLA-A*02:01+ individuals. Using in vitro cultures of three Indigenous
and three non-indigenous donors, we dissected the TCRαβ repertoire
utilised by M158
+CD8+ T cells using a novel single-cell multiplex PCR
for simultaneous amplification of the TCRα and TCRβ chains
(Figure 5).21,28 The repertoires were compared in terms of TCRαβ
gene segment usage, CDR3αβ loop characteristics (important for the
peptide-HLA specificity) and clonal diversity.
Similar to previous reports and our non-indigenous donors
(Figures 5c and d), HLA-A*02:01-restricted M158
+CD8+ T cells
isolated from our LIFT cohort were characterised by a strong
bias for TRBV19 gene segment in TCRβ chain (frequency
of 94.49± 2.11%) and a bias for TRAV27 in the TCRα
chain (39.55± 11.30%, Figures 5a and b, Table 2). As seen in
non-indigenous donors, individuals in the LIFT cohort also displayed
Table 1 Influenza epitopes presented by HLA-A and -B alleles that
are highly prevalent and/or display an ethnic association with
Indigenous Australians
Allele Frequency (LIFT cohort/
NCBI database)


















Abbreviation: LIFT, looking into influenza T-cell immunity.
aNumber of different Influenza epitopes defined in the Immune Epitope Database and Analysis
Resource (available online at http://www.iedb.org/home_v2.php).
bFrequency ⩾10% within the LIFT cohort or NCBI database (for Indigenous Australians).
cAlleles that are unique to Indigenous Australians or particularly associated with this ethnic
group (according to the IPD IMGT/HLA Database available online at http://www.ebi.ac.uk/ipd/
imgt/hla/).
Figure 4 Establishment of robust A2-M158-specific CD8+ T-cell responses in A*02+ Indigenous Australians. A2-M158-specific CD8+ T-cell lines were
generated by pulsing PBMCs from A*02+ donors with M158–66 peptide for 10 days in the presence of rIL-2. Plots (a) show A2-M158 tetramer-PE and
anti-CD8-PerCPCy5.5 staining of CD3+ T cells. Values in parenthesis indicate the proportion of CD8+ T cells that bound A2-M158 tetramer. The function of
A2-M158-specific CD8+ T cells was assessed following peptide stimulation in an ICS assay examining expression of IFN-γ, TNF and CD107a (b, c). Plots (b)
show anti-IFN-γ-V450 and anti-TNF-APC staining of CD3+CD8+ T cells. The polyfunctional profile of M158-specific CD8+ T cells is compared in c.
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a preference for TRBJ2-7 segment within the TCRβ chain
(41.96± 18.14% of clones) and TRAJ42 within the TCRα chain
(54.53± 12.59% of clones). The predominant length of the
complementarity-determining region 3 of TCRβ chain (CDR3β loop),
generally positioned over the centre of the antigenic peptide bound to
HLA class I was of 8 aa (80.21± 9.02% of clones).
Analysis of specific CDR3β and CDR3α sequences showed that
SIRSSYEQ and GGSQGNL were the most common signatures within
the TCRβ–TRBV19 and TCRα–TRAV27, respectively, in accord with
previous reports. Conversely, LIFT donors displayed a preference
for CDR3α lengths of 7 aa (28.97±14.76% of clones), 9 aa
(19.04±8.33% of clones) and 10 aa (19.99±9.27% of clones) in
comparison to non-indigenous individuals, which preferentially selected
CDR3α loops of 9 aa in length (41.75±17.24 of clones), followed by 7 aa
(28.46±18.88 of clones) and 10 aa (23.20±16.63 of clones).
Interestingly, there was a trend towards a higher level of TCR diversity
in Indigenous donors as compared with non-indigenous donors, shown
by an increased number of unique CDR3α (18.33±2.31 versus
10.33±4.73 clonotypes) and CDR3β clones (15.67±2.52 versus
8±2.65 clonotypes) and CDR3αβ pairs (17.67±4.04 versus
11.33±4.62 pairs) per donor. However, these trends were not significant
(P40.05 by a Mann–Whitney test and a non-parametric t-test), most
likely owing to a limited number of donors.
Overall, our data from Indigenous LIFT donors suggest that in
HLA-A*02:01-positive donors A2-M158-specific CD8
+ T cells are
numerically, functionally and clonally comparable to those providing
universal immunity to distinct influenza strains and subtypes in
non-Indigenous populations.11,19,29
Similar pattern of Rs12252-IFITM3 distribution in Indigenous
Australians and Europeans
Rs12252 in interferon-induced transmembrane protein 3 (IFITM3)
can prevent endocytosed virus particles from entering the host
cytoplasm and thus, to some extent, control the viral infection.6 The
SNP rs12252-C variant (C/C genotype), on the other hand, leads to a
21 aa truncation of IFITM3 and is associated with severe outcome
of viral diseases, including influenza A virus, HCV and VSV
infections.6,7,30 High prevalence (30.1%) of rs12252-C/C in East Asia
correlates with influenza disease severity6,7 and indicates that East
Asian populations historically experienced different infection disease
patterns from European people who have an rs12252-C/C frequency
of o1% (Figure 6). Thus, it was of importance to understand the
patterns of SNP rs12252 in Indigenous Australians. Our analysis of
rs12252 distribution patterns in Indigenous people showed similar
patterns in Europeans and Indigenous people (Figure 6), suggesting
that IFITM3-C/C genotype is an unlikely immune correlate for high
Figure 5 A2-M158-specific CD8+ T cells from Indigenous Australians display characteristic TCRαβ repertoire usage. Single A2-M158-specific CD8+ T cells
from (a, b) three representative Indigenous and (c, d) three representative non-Indigenous donors were sorted from day 10–19 in vitro cultures for analysis of
the TCRαβ repertoire using a multiplex PCR and sequencing protocol. (a, c) TRBV and TRAV gene usage was compared across donors and (b, d) clonotype
usage with the prominent BV19/AV27+ subset was further dissected to reveal common usage of a well-defined public A2-M158-specific TCRαβ clonotype.
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influenza disease severity in Indigenous Australians. Furthermore, it is
interesting that while our HLA results (Figures 1–3) showed that
Indigenous people share some similarity in HLA patterns with Asian
populations, which suggests an ancestral link, the IFITM3 genotypes
(Figure 6) are distinct. Considering that African Americans
(AFR_AMR, 5.2%, C/C) have similar rs12252-C/C patterns to their
ancestor Africans (AFR, 6.1%, C/C), it seems that mixing of AFR and
European populations in America two centuries ago did not impose
significant changes in rs12252-C/C distribution. Perhaps distinct
disease burdens have selectively shaped rs12252-C/C distribution in
Asian and Indigenous Australian populations, whereas similar HLA
patterns have been retained.
DISCUSSION
Indigenous populations, including Indigenous Australians and
Alaskans, are at high risk of severe influenza disease.11 In the case of
an emergence of a new influenza viral strain, including avian-derived
influenza viruses such as A/H7N9,9 CD8+ T cells can have an important
role in host recovery. However, pre-existing influenza-specific CD8+
T-cell responses recognising distinct influenza strains and subtypes vary
greatly across ethnicities11 and HLA profiles. We found that while ~15%
of Indigenous Australians (HLA-A*02:01-positive) would have robust
universal CD8+ T-cell pools, epitopes associated with other HLA types
prominent in Indigenous people are unknown.
Our analysis of the LIFT cohort found that Indigenous Australians
display a restricted and distinct HLA profile in accordance with
previously published serological studies.14–16 Our molecular HLA
typing verified the predominant usage of HLA-A*02:01, 11:01,
24:02, 34:01 and HLA-B*13:01, 15:21, 40:01/02, 56:01/02. Such
restriction in HLA diversity and HLA usage is likely to have arisen
from an evolutionary bottleneck that established a small ancestral pool
with limited HLA diversity. As diversity of HLA alleles evolves rapidly,
it is intriguing that there is a high degree of conservation in Indigenous
Australians. This could be partly explained by limited mixing
with other populations, long-term adaptation to local pathogens,
and minimal exposure to new pathogens that might drive selection
and/or emergence of new variants. Limited or no exposure to
influenza prior to European contact in the eighteenth century may
explain a low prevalence of protective HLA variants for influenza.
In addition, we identified two new HLA alleles, HLA-A*02:new and
HLA-B*56:new, in 2 out of 82 LIFT donors. The aa changes in
HLA-A*02:new could potentially impact the repertoire of bound
epitopes. In HLA-A*02:01, Glu 63 is buried in the cleft and likely
interacts with the first residue of the peptide via a network of
hydrogen bonds. Asn 63 of the HLA-A*02:new appears to be too
short to form the same network and may contact the peptide residue 1
via hydrophobic interaction only. Potentially, the HLA-A*02:new
might not be able to bind, or not as stably, the M158 epitope
compared with the HLA-A*02:01 molecule.
Establishment of robust HLA-A*02:01-M158-specific CD8
+ T-cell
responses with a typical magnitude, function and TCRαβ repertoire
structure in HLA-A*02:01-positive Indigenous Australians suggests
that at least ~ 15% of Indigenous Australians would have cross-strain
protective CD8+ T-cell immunity. Once established, M158
+CD8+
T cells can recognise any influenza strain and subtype owing to the
high level of conservation of this epitope.11,19,29 We thus provide the
first data on influenza-specific T-cell immunity in the Indigenous
population. Our findings suggest that where there are shared
HLA profiles between Indigenous Australians and non-Indigenous
populations, they display similar CD8+ T-cell responses to known,
well-characterised influenza epitopes.
With the exception of HLA-A*02:01, little is known about the
peptides presented by HLAs specific to Indigenous Australians
(Table 1). Further studies are required to identify and characterise
epitopes restricted by these unique HLA alleles, in particular HLA-
A*34:01 (frequency of 24% of HLA-A alleles), HLA-B*13:01, 15:21,
Figure 6 Expression of IFITM3 genotype associated with increased influenza disease severity across different ethnicities. Sequencing of the exon 1 region of
IFITM3 containing rs12252 was performed for Indigenous Australians to determine allele frequencies of the SNP rs12252-C variant (in contrast to the WT
rs12252-T variant) associated with increased influenza disease severity. Occurrence of the C/C, T/C and T/T genotypes was determined for this study
population and compared with data for other ethnicities obtained from the 1000 genomes project (available on line at www.1000genomes.org).
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56:01 and 56:02 (together accounting for 43% of HLA-B alleles), to
provide insights into the effectiveness of CD8+ T-cell immunity in this
population. Furthermore, as there is a strong correlation between the
expression of HLA-A*24 and pH1N1 influenza-induced mortality,12
analyses of CD8+ T-cell responses to epitopes restricted by HLA-A*24
alleles in Indigenous Australians are a priority.
Apart from HLA distribution, the expression of IFITM3-C/C SNP
rs12252 represents the only other host factor known to be associated
with increased influenza disease severity across different ethnicities.
Following influenza A virus infection, the expression of IFITM3-C/C
SNP rs12252 is related to an early hypercytokinemia, especially in the
Asian population.6,7 The rs12252-C genotype is reasonably infrequent
in Indigenous Australians, suggesting that compromised IFITM3
function appears not to be linked to the increased susceptibility to
severe influenza disease in this population.
To support the rational design of an effective, broad-spectrum
universal vaccine, it is essential to define the dominant influenza-
specific T-cell responses focused on the allelic HLA variants character-
istic of Indigenous Australians.15,16 Identification of immune and host
factors underlying severe influenza disease in Indigenous Australians,
highly susceptible to influenza, is of an enormous importance.
Understanding which individuals within the Indigenous populations
(globally) are at risk of developing severe influenza disease (for
example, HLA-A24-expressing individuals12) will inform our future
prognostic strategies for the treatment and management of severe
influenza pneumonia and for designing the vaccination programmes
that target specific groups for routine influenza immunisation.
METHODS
Human ethics
All the experiments conformed to the NHMRC Code of Practice and were
approved by the University of Melbourne Research Human Ethics Committee
(Applications #1441452.1 and #0931311.5) and the Human Research Ethics
Committee of Northern Territory Department of Health and Menzies School of
Health Research (Application # HREC-2012-1928).
Recruitment of Indigenous Australian donors (LIFT cohort)
To understand influenza-specific responses in the Indigenous population,
participants ⩾ 18 years of age were recruited from the Royal Darwin Hospital
and also from healthy volunteers in Darwin as a ‘looking into influenza T-cell
immunity’ (LIFT) cohort. We ensured representation of different age groups
across the main regions of the Top End (Darwin urban, Darwin rural, West
Arnhem/Daly, Tiwi Islands, East Arnhem, Katherine). This permitted sampling
from a range of language and people groups so as not to bias the population
HLA distribution. For hospital inpatients, permissions were requested from the
treating clinical team for the research team to approach potential participants.
Patients were then approached to discuss the study and seek informed consent
for access to medical and immunisation records and to obtain a 50-ml venous
blood sample. Participants were excluded if they had a diagnosis of
Systemic Inflammatory Response (SIRS) (defined as satisfying ⩾ 2 SIRS
criteria–temperature o36 °C or 438 °C; heart rate490 b.p.m.; respiratory
rate420 b.p.m.; white blood cell count o4× 109 per l or412× 109 per l) or a
haemoglobin below the normal range. Participant recruitment, sample
collection, isolation by Ficoll Paque density centrifugation (GE Healthcare,
Uppsala, Sweden)20 and storage of PBMCs were performed at the Menzies
School of Health Research. PBMCs were cryopreserved for further use at
University of Melbourne. DNA was isolated from granulocytes using a
QIAGEN QIAamp DNA Mini Kit (QIAGEN, Hilder, Germany) according to
manufacturer’s instructions.
PBMC isolation from buffy packs
PBMCs were isolated also from buffy packs (obtained from the Blood Bank,
Melbourne, VIC, Australia) for HLA-A*02:01+ non-Indigenous donors. PBMCs
were isolated by Ficoll Paque density centrifugation,20 then cryopreserved for
future use. Viability of the PBMCs derived from the Indigenous donors was
480% (80–95%) upon thawing out. Furthermore, a viability stain (Live/dead
stain) was used in all ICS assays to confirm that all detected responses are from
viable CD8+ T cells. A 485% viability was detected in all CD8+ T-cell lines
derived from Indigenous donors following the ICS assay.
HLA typing and IFITM3 genotyping
HLA class I and class II molecular genotyping was performed from genomic
DNA by the Victorian Transplant and Immunogenetics Service (Parkville,
Melbourne, VIC, Australia). For IFITM3 sequencing, the exon 1 region of
IFITM3 containing rs12252 was amplified from genomic DNA by PCR with
forward (5′-GGAAACTGTTGAGAAACCGAA-3′) and reverse (5′-CATACG
CACCTTCACGGAGT-3′) primers, as previously described.7
Generation of M158-specific CD8+ T-cell lines
To amplify influenza-specific CD8+ T cells directed at the immunodominant
HLA-A*02:01-restricted M158-66 epitope, PBMCs from HLA-A*02 donors were
stimulated with the M158-66 (GILGFVFTL) peptide and then cultured for 10
to 19 days, as previously described.20,31 Cultures were supplemented twice
weekly with 10 Uml− 1 rIL-2 and CD8+ T-cell lines from non-indigenous
donors were restimulated once weekly with gamma-irradiated M158-pulsed
C1R-A*02:01 cells.
Intracellular cytokine staining (ICS)
At d10, HLA-A*02-M158
+CD8+ T cells from Indigenous donors were assessed
by an IFN-γTNF/CD107a ICS assay. C1R-A*02:01+ were used as antigen
presenting cells (APCs) in an ICS assay to restimulate PBMCs. APCs
(at 1–3× 107 cells per ml) were pulsed with 10 μM peptide in 100 μl serum-
free media RPMI for 60min at 37 °C. Subsequently, 1 × 105 peptide-pulsed
APCs were co-cultured with 2× 105 restimulated PBMC samples for 5 h at
37 °C in U-bottom 96-well plates in the presence of IL-2 (10 Uml− 1), 2 μl
GolgiPlug (BD Biosciences, Franklin Lakes, NY, USA; final dilution of 1:1000)
and 1.33 μl Golgi-Stop (BD Biosciences, final dilution of 1:1500) and 1 μl anti-
CD107a-AF488 (eBiosceinces, San Diego, CA, USA). Following stimulation,
cells were washed with FACS buffer (1% bovine serum albumin (Gibco,
Waltham, MA, USA) and 0.02% sodium azide (Sigma, St Louis, MO, USA) in
phosphate-buffered saline (PBS)) and stained with anti-CD3-PeCy7 (eBios-
ceinces) and anti-CD8α-PerCP-Cy5.5 (BD Biosciences) and Live/Dead-NIR
(Invitrogen, Carlsbad, CA, USA) in PBS, and then washed twice. Cells were
fixed and permeabilised using the BD Cytofix/Cytoperm Plus Fixation/
Permeabilisation Kit (BD Biosciences), and intracellularly-stained with anti-
IFN-γ-V450 (BD Horizon, Franklin Lakes, NY, USA), anti-TNF-APC (BD
Biosceinces) in perm-wash buffer. Samples were washed and acquired by flow
cytometry on a BD FACS Canto II (BD Biosciences) and analysed by FlowJo
software (Treestar, Ashland, OR, USA). Cytokine production was calculated by
subtracting background fluorescence using ‘no peptide’ C1R-A*02:01+ controls.
Tetramer staining
D10-19 M158 cultures were stained with HLA-A*02:01-M158 tetramer
conjugated to PE or APC at a 1:100 dilution in FACS buffer (PBS with 0.1%
bovine serum albumin) or PBS. Cells were then washed twice with cold FACS
buffer and stained with a cocktail of antibodies including anti-CD3-PB
(Biolegend) or anti-CD3-PeCy7 (eBiosciences), anti-CD8-PerCPCy5.5 or anti-
CD8-PerCP (both BD Biosciences), CD27-APC or APC-Cy7 (BD Biosciences),
CD45RA-FITC (BD Pharmingen, San Diego, CA, USA) and Live/Dear-NIR
(Invitrogen) (Indigenous donors only), washed twice with FACS buffer or PBS.
Cells were then resuspended in 200 μl of sort buffer and passed though a 40-μm
sieve prior to flow cytometric analysis or sorting.
Single-cell multiplex RT-PCR for paired CDR3β and CDR3α analysis
CD8+ T cell lines were tetramer-stained as above and single HLA-A*02:01-
M158-tetramer
+ CD3+dump-CD8+tetramer+ cells were single-cell sorted on a
FACS Aria III (BD Biosciences) into 80 wells of a 96-well twin-tec plate
(Eppendorf, Hamburg, Germany). The CDR3αβ regions were determined by a
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novel single-cell multiplex reverese transcription PCR (RT-PCR) protocol.21,28
mRNA transcripts were reverse-transcribed to cDNA, using a VILO kit
(Invitrogen). For the internal round of PCR, 2.5 μl of the external product
was used as template, with either a set of TRAV or TRBV internal primers.28
The internal PCR reaction included the two different primers sets at 5
pmol ml− 1 (TRAV and TRAC, or TRBV and TRBC). Positive PCR products
were purified with Exo-SAP-IT (Affymetrix, Santa Clara, CA, USA) and
sequenced using TRAC or TRBC internal primers with BigDye v3.1 (Applied
Biosciences, Foster City, CA, USA). Sequences were cleaned using DyeEx
sequencing plates (QIAGEN) and sequencing was performed at the Sequencing
and Genotyping facility within the Department of Pathology at the University of
Melbourne. Sequences were analysed using FinchTV, and V and J region usage
was identified by IMGT query (www.imgt.org/IMGT_vquest).
New HLA class I modelling
The HLA-A*02:new model was made using the published HLA-A*02:01
structure (PDB code: 3GSO20) and mutating the corresponding residues:
glycine 62 to arginine, glutamic acid 63 to asparagine. The HLA-B*56:new
was modelled using the HLA-B*57:01 structure (PDB code: 3VRI32) and
mutating the residue 75 from arginine to glycine. All the mutations have been
generated in Pymol.33
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